CHRS

UDENYCA® (pegfilgrastim-cbqv) Biosimilar

Oncology

Quarterly Sales (Approved)

Exp Date

November 6, 2020 (Est)

Amp Volatility Score

Catalyst Info & Data Links

POSTERS


PRESENTATIONS


PUBLICATIONS

MECHANISM OF ACTION / RATIONALE

  • Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. 


  • source - FDA Label (section 12.1)

Updated by HC

#CHRS, #UDENYCA, #pegfilgrastim-cbqv

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

CHRS Reports Q2 2020 UDENYCA® ...

#CHRS reports their second quarter of #UDENYCA® Net Sales of $135.7 Million. See our AmpCard for more details. #CHRS, #UDENYCA...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon